Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM2012 in Advanced Solid Tumors
NCT07100249Phase 1Recruiting
- Sponsor
- Huadong Medicine
- Start
- Aug 2025
- Primary completion
- Oct 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HDM2012 in solid tumor (advanced stage), gastric cancer (GC) and colorectal cancer (CRC), sponsored by Huadong Medicine. Primary endpoints: Incidence of Dose Limiting Toxicity at 21 days, Incidence and Severity of Adverse Events and 2 more. Started Aug 2025; status: recruiting.
02
Drugs
HDM2012
03
Conditions
solid tumor (advanced stage)gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07100249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07100249.